
Data ownership as leverage in accelerating rare disease drug development? Finally, there’s a cloud software that empowers patient groups!
Patient groups can optimize patient registries, cross-sectional studies, and/or longitudinal natural history studies to maximize collaborations with sponsors of orphan drugs and gene therapies